Purinergic Receptor Expression and Potential Association with Human Embryonic Stem Cell-Derived Oligodendrocyte Progenitor Cell Development
Objective: Due to recent progress in production of human embryonic stem cell-derived oligodendrocyte progenitor cells (hESC-OPCs) for ameliorating myelin disease such as multiple sclerosis (MS) and the role of purinergic signaling in OPCs development, we avaluated the profile of purinergic recept...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Royan Institute (ACECR), Tehran
2017-08-01
|
| Series: | Cell Journal |
| Subjects: | |
| Online Access: | http://celljournal.org/journal/article/14342/download |
| Summary: | Objective: Due to recent progress in production of human embryonic stem cell-derived
oligodendrocyte progenitor cells (hESC-OPCs) for ameliorating myelin disease
such as multiple sclerosis (MS) and the role of purinergic signaling in OPCs development,
we avaluated the profile of purinergic receptors expression during development
of OPCs from hESC.
Materials and Methods: In this experimental study, we used reverse transcription and
quantitative polymerase chain reaction (RT-qPCR) to obtain more information about
potential roles of purinergic receptors during in vitro production of hESC-OPCs. We
first determined the expression level of different subtypes of purinergic receptors in
hESCs, embryoid bodies (EBs), and hESC-OPCs. The effects of A1 adenosine receptor
(A1AR) activation on hESC-OPCs development were subsequently examined.
Results: hESCs and OPCs had different mRNA expression levels of the AR subtypes.
ARs mRNA were expressed in the EB stage, except for A2AAR. We observed expressions
of several P2X (P2X1, 2, 3, 4, 5, 7) and P2Y (P2Y1, 2, 4, 6, 11-14) genes in hESCs. hESC-OPCs expressed
different subtypes of P2X (P2X1, 2, 3,4,5,7) and P2Y (P2Y1, 2, 4, 6, 11-14). Except for P2X1
and P2X6, all other P2X and P2Y purinergic receptor subtypes expressed in EBs. We also
indicate that A1AR might be involved in modulating gene expression levels of cell cycle
regulators in an agonist and/or dose-dependent manner.
Conclusion: Elucidation of the expression pattern of purinergic receptors and the effects
of different subtypes of these receptors in hESC-OPCs may have a promising role in future
cell-based therapy or drug design for demyelinating disease. |
|---|---|
| ISSN: | 2228-5806 2228-5814 |